COTI-2's specific cellular targeting, low toxicity, and proven efficacy
support a potentially dramatic change in the treatment of susceptible
cancers consistent with the views expressed at ASCO. Over expression of
Akt/Akt2 is common in a broad range of human cancers, including ovarian,
endometrial, pancreatic, breast, colorectal and lung. The percent of
tumors with active Akt/Akt2 range from 20% to 100% depending on the
cancer type.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge company specializing in accelerating
the discovery of small molecules to enable new drugs to be brought to
market in a more cost effective, efficient and timely manner. COTI'S
proprietary artificial intelligence system, CHEMSAS®, utilizes a series
of predictive computer models to identify compounds most likely to be
successfully incorporated in disease-specific drug discovery, as well as
subsequent optimization and preclinical development. These compounds
are targeted for a variety of diseases, particularly those for which
current treatments are either lacking or ineffective.
